Leukemia ASH 2024 Highlights - Menin Inhibitors, CPX 351 vs 7+3, Venetoclax Based Regimens

4 Views

  • Thanks! Share it with your friends!

    You disliked this video. Thanks for the feedback!

admin
Published
Welcome back to the Oncology Brothers podcast! In this episode, we dive into the highlights from ASH 2024, focusing on key studies in leukemia. Join hosts Drs. Rahul and Rohit Gosain as they discuss groundbreaking research with Dr. Uma Borate from The Ohio State University.

Episode Highlights:
•⁠ ⁠KOMET 007 Study: An in-depth look at the Phase 1 study on the Menin inhibitor Ziftomenib, exploring its promising results in frontline settings for patients with NPM1 mutations and KMT2A rearrangements.
•⁠ ⁠CPX351 vs. 7+3 Induction: A discussion on the liposomal formulation CPX351 and its effectiveness compared to the traditional 7+3 induction therapy, particularly in patients with myelodysplasia-related AML.
•⁠ ⁠Venetoclax Combinations: Insights into the use of Venetoclax in combination with various therapies, including its role in treating patients without actionable mutations.

Key Takeaways:
•⁠ ⁠The importance of NGS testing in identifying targetable mutations in AML.
•⁠ ⁠Promising response rates and manageable toxicities associated with Menin inhibitors.
•⁠ ⁠The ongoing debate regarding the best induction therapy for AML patients.

Don't miss this informative discussion that sheds light on the evolving landscape of leukemia treatment!

Subscribe for more updates on oncology topics, including lymphoma, CLL, and myeloma discussions from ASH 2024. Thanks for tuning in! We are the Oncology Brothers.

Website: http://www.oncbrothers.com/

X/Twitter: https://twitter.com/oncbrothers

Contact us at [email protected]
Category
Oncology
Be the first to comment

Up Next